Drugs / Sertraline
last change 3 days ago re-read 2 minutes ago

Sertraline

Small molecule targets SLC6A4 via inhibition

Developed for
major depressive disorder · depressive disorder · post-traumatic stress disorder · alcohol dependence · obsessive-compulsive disorder · bipolar disorder · schizophrenia · anxiety disorder
+53 more · dysthymic disorder · coronary artery disorder · dementia · generalized anxiety disorder · panic disorder · social phobia · Alzheimer disease · anxiety · bipolar depression · cocaine dependence · hepatitis C virus infection · obesity disorder · postpartum depression · premenstrual dysphoric disorder · premenstrual tension · stereotypic movement disorder · traumatic brain injury · acute myeloid leukemia · acute stress disorder · agoraphobia · autism · bipolar II disorder · cardiac rhythm disease · chronic pain syndrome · cirrhosis of liver · coccidioidomycosis · Cryptococcal meningitis · cryptococcosis · fragile X syndrome · gastroesophageal reflux disease · glioblastoma · Huntington disease · hypertensive disorder · impulse control disorder · mental disorder · migraine disorder · mixed anxiety and depressive disorder · myelodysplastic syndrome · Parkinson disease · phobic disorder · premature menopause · uremia · alcohol abuse · autism spectrum disorder · burning mouth syndrome · chronic kidney disease · conversion disorder · melancholia · mood disorder · pathological gambling · psychotic disorder · separation anxiety disorder · sexual disorder
Investigated by
National Institute of Mental Health (NIMH) · Pfizer · Duke University · Massachusetts General Hospital · National Institute on Alcohol Abuse and Alcoholism (NIAAA) · Samsung Medical Center
+193 more · Centre for Addiction and Mental Health · University of Pennsylvania · University of Sao Paulo · Vanderbilt University · Viatris Inc. · Yale University · Columbia University · Emory University · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · First Affiliated Hospital of Chongqing Medical University · University of Minnesota · Eli Lilly and Company · Federal University of Rio Grande do Sul · Indiana University · Johns Hopkins University · Mclean Hospital · National Heart, Lung, and Blood Institute (NHLBI) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · National Institute of Neurological Disorders and Stroke (NINDS) · New York State Psychiatric Institute · Otsuka Pharmaceutical Development & Commercialization, Inc. · University of California, San Francisco · University of Pittsburgh · Actavis Inc. · Baylor College of Medicine · Dr. Inge Winter · Hamilton Health Sciences Corporation · MaineHealth · Mayo Clinic · Mbarara University of Science and Technology · McMaster University · Medical Research Council · Mylan Pharmaceuticals Inc · National Institute on Drug Abuse (NIDA) · National Institutes of Health (NIH) · Nova Scotia Health Authority · Ontario Mental Health Foundation · Second Affiliated Hospital, School of Medicine, Zhejiang University · Stanford University · São Paulo Research Foundation · Teva Pharmaceuticals USA · University Health Network, Toronto · University of California, Los Angeles · University of Florida · University of Münster · Zhejiang University · 59th Medical Wing · Action Research Group · Ajay Wasan, MD, Msc · Alexandria University · Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · Alto Neuroscience · Amsterdam UMC, location VUmc · Anticancer Fund, Belgium · Assistance Publique - Hôpitaux de Paris · Beijing HuiLongGuan Hospital · Boston University Charles River Campus · Bristol-Myers Squibb · Brown University · Caecilie Buhmann · Capital Medical University · Central Hospital, Nancy, France · Centre Hospitalier Universitaire Dijon · Centre Hospitalier Universitaire Vaudois · Children's Hospital of Chongqing Medical University · Dalian Seventh People's Hospital · Demensforbundet, Norway · Dow University of Health Sciences · Dr. Nazanin Alavi · Duke Kunshan University · First Hospital of China Medical University · Forest Laboratories · GlaxoSmithKline · Guang Dong Provincial Mental Health Institute · all 199 on the full record

Regulatory milestones approvals, filings & regulatory actions · 12 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Label expansions (11) US (FDA) ZOLOFT 1996-10-25 – 2004-08-19 fda.gov
Approved US (FDA) ZOLOFT 1991-12-30 fda.gov

Trials 186 · started per year

today
US approved 1991
1
1
1
4
2
5
4
8
16
12
11
6
7
3
9
5
8
5
5
10
6
5
10
2
4
5
4
3
5
4
3
5
5
19911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 02 trials
Phase 0 NCT06796946 Jun → Dec 2026 expected University of Huelva Not yet recruiting No outcome recorded
Phase 0 NCT02269540 Oct 2014 → Jun 2018 major depressive disorder Centre for Addiction and Mental Health Completed No outcome recorded
Phase 120 trials
Phase 1 NCT07139834 Jun 2026 → Jun 2027 expected major depressive disorder Jeffrey Miller Recruiting No outcome recorded
Phase 1 NCT04071639 Mar 2020 → Dec 2024 Huntington disease Second Affiliated Hospital, School of Medicine, Zhejiang University Unknown No outcome recorded
Phase 1 NCT02891278 Aug 2016 → Nov 2020 acute myeloid leukemia Columbia University Completed No outcome recorded
Phase 1 NCT02651623 Jan → Sep 2016 Viatris Inc. Completed No outcome recorded
Phase 1 NCT02452983 May 2015 → Nov 2020 myelodysplastic syndrome Gustavo Rivero Terminated No outcome recorded
Phase 1 NCT02175602 Jun → Aug 2014 hepatitis C virus infection Bristol-Myers Squibb Completed No outcome recorded
Phase 1 NCT01669304 Aug 2012 → Oct 2014 migraine disorder Mayo Clinic Completed No outcome recorded
Phase 1 NCT01250873 Nov 2010 → Jan 2011 major depressive disorder Eli Lilly and Company Completed No outcome recorded
Phase 1 NCT01155531 May → Aug 2010 obesity disorder Theracos Completed No outcome recorded
Phase 1 NCT01113164 Sep 2008 → Feb 2012 alcohol dependence Brown University Completed No outcome recorded
Phase 1/28 trials
Phase 1/2 NCT05814640 Feb 2023 → Dec 2026 expected major depressive disorder, splenic sequestration First Affiliated Hospital of Chongqing Medical University Recruiting No outcome recorded
Phase 1/2 NCT02770378 Nov 2016 → Oct 2018 glioblastoma University of Ulm Completed No outcome recorded
Phase 1/2 NCT02797808 Aug 2013 → Jan 2017 obsessive-compulsive disorder University of Minnesota Completed No outcome recorded
Phase 1/2 NCT01032018 Jan 2010 → Jan 2012 acute coronary syndrome, depressive disorder Columbia University Completed No outcome recorded
Phase 1/2 NCT00133822 Apr 2004 → Sep 2006 post-traumatic stress disorder Emory University Completed No outcome recorded
Phase 1/2 NCT00048854 Sep 2001 → Jun 2007 premenstrual tension Yale University Completed No outcome recorded
Phase 1/2 NCT00581009 May 2001 → Dec 2011 bipolar disorder, major depressive disorder University of California, Irvine Completed No outcome recorded
Phase 1/2 NCT00262470 Apr 1997 → Dec 2029 expected cardiac rhythm disease Satish R. Raj Active not recruiting No outcome recorded
Phase 227 trials
Phase 2 NCT07645157 Oct 2026 → Oct 2028 expected major depressive disorder First Affiliated Hospital of Chongqing Medical University Recruiting No outcome recorded
Phase 2 NCT05341843 May → Sep 2022 uremia Alexandria University Completed No outcome recorded
Phase 2 NCT05002309 Dec 2021 → Jun 2028 expected major depressive disorder Nova Scotia Health Authority Recruiting No outcome recorded
Phase 2 NCT04437485 Oct 2020 → Aug 2022 dysthymic disorder, major depressive disorder, prediabetes syndrome, type 2 diabetes mellitus Indiana University Completed No outcome recorded
Phase 2 NCT04171193 Dec 2019 → Sep 2020 major depressive disorder University of Sao Paulo Unknown No outcome recorded
Phase 2 NCT03222570 Feb 2018 → Apr 2024 depressive disorder University of Minnesota Completed No outcome recorded
Phase 2 NCT03033069 Jan 2017 → Nov 2018 post-traumatic stress disorder Otsuka Pharmaceutical Development & Commercialization, Inc. Completed No outcome recorded
Phase 2 NCT02908334 Nov 2016 → Jan 2019 coccidioidomycosis University of California, San Francisco Withdrawn No outcome recorded
Phase 2 NCT02458690 Jul 2015 → Aug 2019 coronary artery disorder, dysthymic disorder, major depressive disorder, stroke disorder Indiana University Completed No outcome recorded
Phase 2 NCT01977729 Oct 2013 → Sep 2014 anxiety disorder Yale University Terminated No outcome recorded
Phase 2/38 trials
Phase 2/3 NCT04747314 Mar 2021 → Nov 2024 anxiety, chronic pain syndrome Ajay Wasan, MD, Msc Completed No outcome recorded
Phase 2/3 NCT01033084 Dec 2009 → Dec 2011 major depressive disorder University of Sao Paulo Completed No outcome recorded
Phase 2/3 NCT00767624 Dec 2008 → Jun 2015 major depressive disorder, sleep disorder, initiating and maintaining sleep Stanford University Completed No outcome recorded
Phase 2/3 NCT00704379 Jun 2008 → Apr 2014 traumatic brain injury Baylor College of Medicine Completed No outcome recorded
Phase 2/3 NCT00086138 Jul 2004 → Jul 2008 Alzheimer disease, depressive disorder Johns Hopkins University Completed No outcome recorded
Phase 2/3 NCT00080158 Mar 2004 → Jun 2007 depressive disorder New York State Psychiatric Institute Completed No outcome recorded
Phase 2/3 NCT00078286 Nov 2003 → Mar 2008 congestive heart failure, depressive disorder Duke University Completed No outcome recorded
Phase 2/3 NCT00118417 Mar 1999 → Oct 2007 panic disorder Massachusetts General Hospital Completed No outcome recorded
Phase 320 trials
Phase 3 NCT05603104 Apr 2025 → Jun 2028 expected bipolar depression, major depressive disorder, schizophrenia Dr. Inge Winter Recruiting No outcome recorded
Phase 3 NCT05973786 Feb 2025 → Jun 2028 expected bipolar depression Dr. Inge Winter Recruiting No outcome recorded
Phase 3 NCT05950061 Jun → Oct 2022 major depressive disorder KRL Hospital, Islamabad Completed No outcome recorded
Phase 3 NCT04174170 Oct 2019 → Jul 2023 post-traumatic stress disorder Otsuka Pharmaceutical Development & Commercialization, Inc. Completed No outcome recorded
Phase 3 NCT04124614 Oct 2019 → Jul 2023 post-traumatic stress disorder Otsuka Pharmaceutical Development & Commercialization, Inc. Completed No outcome recorded
Phase 3 NCT03002012 Nov 2017 → Mar 2018 cryptococcosis University of Minnesota Terminated No outcome recorded
Phase 3 NCT01802385 Mar 2015 → Sep 2017 Cryptococcal meningitis University of Minnesota Completed No outcome recorded
Phase 3 NCT02374567 Jan 2015 → Jun 2017 anxiety disorder, dementia, depressive disorder, schizophrenia +1 Hannover Medical School Terminated No outcome recorded
Phase 3 NCT01214382 Oct 2010 → Aug 2014 North Dakota State University Completed No outcome recorded
Phase 3 NCT00276965 Sep 2006 → Mar 2012 bipolar II disorder, depressive disorder Lindner Center of HOPE Completed No outcome recorded
Phase 459 trials
Phase 4 NCT07552246 Apr 2026 → Mar 2027 expected mixed anxiety and depressive disorder Duke Kunshan University Not yet recruiting No outcome recorded
Phase 4 NCT07011693 Jun 2025 → Jun 2027 expected major depressive disorder Xinyu Zhou Not yet recruiting No outcome recorded
Phase 4 NCT06357104 Feb → Mar 2024 Pachankis, Yang I., M.D. Completed No outcome recorded
Phase 4 NCT05892744 Sep 2023 → Jul 2027 expected major depressive disorder University of Texas at Austin Recruiting No outcome recorded
Phase 4 NCT05537584 Sep 2022 → Aug 2025 major depressive disorder Mclean Hospital Completed No outcome recorded
Phase 4 NCT06124417 Jan 2022 → Aug 2023 drug allergy First Affiliated Hospital of Chongqing Medical University Completed No outcome recorded
Phase 4 NCT04388202 Oct 2020 → May 2023 major depressive disorder Alto Neuroscience Withdrawn No outcome recorded
Phase 4 NCT04221997 Nov 2019 → Sep 2026 expected anxiety disorder University of Cincinnati Recruiting No outcome recorded
Phase 4 NCT03711708 Nov 2018 → Feb 2019 Viatris Inc. Completed No outcome recorded
Phase 4 NCT03993535 Oct 2018 → Apr 2023 obsessive-compulsive disorder University of Sao Paulo Completed No outcome recorded
Phase not applicable42 trials
NCT07654179 Jun 2026 → Jun 2027 expected depressive disorder, obesity disorder Riphah International University Recruiting No outcome recorded
NCT06384209 Jun 2025 → Dec 2027 expected major depressive disorder University of Bern Recruiting No outcome recorded
NCT07015944 Jun 2025 → Dec 2028 expected breast cancer, major depressive disorder Pakistan Institute of Living and Learning Recruiting No outcome recorded
NCT06840379 Oct 2024 → Apr 2025 overdue end stage renal failure Nishtar Medical University Active not recruiting No outcome recorded
NCT06778824 Apr 2024 → Dec 2025 overdue gastroesophageal reflux disease Hualien Tzu Chi General Hospital Recruiting No outcome recorded
NCT06001021 Aug → Sep 2023 mental disorder Sameera Shafiq Completed No outcome recorded
NCT05683223 May 2023 → Apr 2027 expected social phobia Boston University Charles River Campus Recruiting No outcome recorded
NCT06725771 Sep 2022 → Oct 2024 generalized anxiety disorder Lin Xiaoqian Completed No outcome recorded
NCT03841474 Mar → Jun 2021 coronary artery disorder, depressive disorder University Hospital Centre Zagreb Unknown No outcome recorded
NCT04478526 Apr 2020 → May 2021 generalized anxiety disorder Dr. Nazanin Alavi Completed No outcome recorded
Also used as a comparator or background therapy in 154 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 16 trials
Phase 1 NCT06965569 Background Apr → Dec 2025 Alar Pharmaceuticals Inc. Completed No outcome recorded
Phase 1 NCT03514810 Background Jan → Sep 2017 major depressive disorder Kufa University Completed No outcome recorded
Phase 1 NCT03469128 Comparator Jan 2016 → Jan 2020 British University In Egypt Completed No outcome recorded
Phase 1 NCT01347541 Background Jan → Nov 2011 post-traumatic stress disorder University of Washington Terminated No outcome recorded
Phase 1 NCT01235195 Comparator Nov → Dec 2010 Viatris Inc. Completed No outcome recorded
Phase 1/22 trials
Phase 1/2 NCT02917122 Comparator Aug 2015 → Aug 2021 Parkinson disease, depressive disorder National Cheng-Kung University Hospital Terminated No outcome recorded
Phase 1/2 NCT00612807 Background Jul 2006 → Jun 2010 major depressive disorder Duke University Completed No outcome recorded
Phase 223 trials
Phase 2 NCT07539805 Background Jun 2026 → Feb 2028 expected major depressive disorder First Affiliated Hospital of Chongqing Medical University Recruiting No outcome recorded
Phase 2 NCT06408246 Background Mar 2026 → Oct 2028 expected depressive disorder Stanford University Recruiting No outcome recorded
Phase 2 NCT06081348 Comparator Sep 2024 → Sep 2026 expected Tourette syndrome, anxiety, attention deficit hyperactivity disorder, inattentive type, autism +3 Holland Bloorview Kids Rehabilitation Hospital Recruiting No outcome recorded
Phase 2 NCT05646693 Background Dec 2022 → Dec 2023 tinnitus University of Guadalajara Unknown No outcome recorded
Phase 2 NCT04539951 Comparator Sep 2020 → Jun 2027 expected obsessive-compulsive disorder Shanghai Mental Health Center Recruiting No outcome recorded
Phase 2/35 trials
Phase 2/3 NCT07574060 Comparator May 2026 → May 2027 expected major depressive disorder Tanta University Not yet recruiting No outcome recorded
Phase 2/3 NCT02565316 Comparator Nov 2014 → Mar 2015 anxiety, depressive disorder Shiraz University of Medical Sciences Completed No outcome recorded
Phase 2/3 NCT00299611 Comparator Nov 2005 → Dec 2007 obsessive-compulsive disorder Duke University Terminated No outcome recorded
Phase 2/3 NCT00215241 Background Apr 2004 → Jul 2006 post-traumatic stress disorder Duke University Completed No outcome recorded
Phase 2/3 NCT00340379 Comparator Apr 2003 → Aug 2005 mood disorder Duke University Completed No outcome recorded
Phase 339 trials
Phase 3 NCT06827431 Comparator Feb 2025 → Jun 2026 overdue major depressive disorder CSPC ZhongQi Pharmaceutical Technology Co., Ltd. Not yet recruiting No outcome recorded
Phase 3 NCT06025474 Comparator Jan → Oct 2023 burning mouth syndrome Federico II University Unknown No outcome recorded
Phase 3 NCT06698666 Background Oct 2022 → Dec 2024 overdue major depressive disorder Ain Shams University Recruiting No outcome recorded
Phase 3 NCT04598230 Comparator Feb 2021 → Aug 2025 overdue generalized anxiety disorder, separation anxiety disorder, social phobia Ann & Robert H Lurie Children's Hospital of Chicago Active not recruiting No outcome recorded
Phase 3 NCT04476030 Background Nov 2020 → Oct 2021 major depressive disorder Biogen Completed No outcome recorded
Phase 445 trials
Phase 4 NCT06704594 Comparator May 2025 → Jul 2029 expected premenstrual dysphoric disorder Johns Hopkins University Recruiting No outcome recorded
Phase 4 NCT07478796 Comparator Apr 2025 → Nov 2027 expected major depressive disorder Poznan University of Medical Sciences Recruiting No outcome recorded
Phase 4 NCT07192367 Comparator Nov 2024 → Aug 2026 overdue social phobia Emine Kanmaz Recruiting No outcome recorded
Phase 4 NCT05273996 Background Sep 2021 → Apr 2027 expected major depressive disorder, neurotic disorder David Steffens Active not recruiting No outcome recorded
Phase 4 NCT04597190 Comparator Jun 2020 → Aug 2024 post-traumatic stress disorder University of Washington Completed No outcome recorded
Phase not applicable34 trials
NCT07318181 Comparator Jan 2026 → Nov 2027 expected post-traumatic stress disorder University of Luxembourg Recruiting No outcome recorded
NCT06955845 Comparator May → Nov 2025 post-traumatic stress disorder Asad Ullah Jan Completed No outcome recorded
NCT06957223 Comparator May → Nov 2025 major depressive disorder Asad Ullah Jan Completed No outcome recorded
NCT06942494 Comparator Apr 2025 → Aug 2027 expected obsessive-compulsive disorder Shanghai Mental Health Center Recruiting No outcome recorded
NCT07025590 Comparator Apr 2025 → Dec 2026 expected cardiovascular disorder, mixed anxiety and depressive disorder Guangdong Provincial People's Hospital Recruiting No outcome recorded

Press releases naming this drug 20 releases

DateIssuerRelease
2025-09-20 Otsuka Pharmaceutical Development & Commercialization, Inc. Otsuka and Lundbeck Receive Complete Response Letter from U.S. FDA for sNDA of REXULTI (brexpiprazole) in Combination with Sertraline for the Treatment of Adults with Post-Traumatic Stress Disorder (PTSD)® otsuka.co.jp
2025-09-20 Otsuka Pharmaceutical Development & Commercialization, Inc. Otsuka and Lundbeck Receive Complete Response Letter from U.S. FDA for sNDA of REXULTI® (brexpiprazole) in Combination with Sertraline for the Treatment of Adults with Post-Traumatic Stress Disorder (PTSD) otsuka-us.com
2025-07-19 Otsuka Pharmaceutical Development & Commercialization, Inc. Otsuka and Lundbeck Issue Statement on U.S. Food and Drug Administration (FDA) Advisory Committee Meeting on REXULTI (brexpiprazole) in Combination with Sertraline for the Treatment of Adults with Post-Traumatic Stress Disorder (PTSD)® otsuka.co.jp
2025-01-10 Otsuka Pharmaceutical Development & Commercialization, Inc. Otsuka Announces FDA Plans to Host an Advisory Committee Meeting to Discuss the sNDA for Brexpiprazole in Combination with Sertraline for the Treatment of Adults with Post-Traumatic Stress Disorder (PTSD) otsuka.co.jp
2025-01-10 Otsuka Pharmaceutical Development & Commercialization, Inc. Otsuka Announces FDA Plans to Host an Advisory Committee Meeting to Discuss the sNDA for Brexpiprazole in Combination with Sertraline for the Treatment of Adults with Post-Traumatic Stress Disorder (PTSD) otsuka-us.com
2024-12-19 Otsuka Pharmaceutical Development & Commercialization, Inc. JAMA Psychiatry Publishes Results of Otsuka and Lundbeck's Phase 3 Trial of Brexpiprazole in Combination with Sertraline in Treatment of Post-Traumatic Stress Disorder (PTSD) in Adults otsuka.co.jp
2024-12-18 Otsuka Pharmaceutical Development & Commercialization, Inc. JAMA Psychiatry Publishes Results of Otsuka and Lundbeck's Phase 3 Trial of Brexpiprazole in Combination with Sertraline in Treatment of Post-Traumatic Stress Disorder (PTSD) in Adults otsuka-us.com
2024-06-25 Otsuka Pharmaceutical Development & Commercialization, Inc. Otsuka and Lundbeck announce FDA acceptance of sNDA filing for brexpiprazole in combination with sertraline for the treatment of adults with post-traumatic stress disorder (PTSD) otsuka.co.jp
2024-06-25 Otsuka Pharmaceutical Development & Commercialization, Inc. Otsuka and Lundbeck Announce FDA Acceptance of sNDA Filing for Brexpiprazole in Combination with Sertraline for the Treatment of Adults with Post-Traumatic Stress Disorder (PTSD) otsuka-us.com
2024-05-29 Otsuka Pharmaceutical Development & Commercialization, Inc. Otsuka and Lundbeck Present Results from Three Clinical Trials of Brexpiprazole in Combination with Sertraline for the Treatment of Post-Traumatic Stress Disorder (PTSD) in Adults otsuka.co.jp
2024-05-28 Otsuka Pharmaceutical Development & Commercialization, Inc. Otsuka and Lundbeck Present Results from Three Clinical Trials of Brexpiprazole in Combination with Sertraline for the Treatment of Post-Traumatic Stress Disorder (PTSD) in Adults otsuka-us.com
2024-04-10 Otsuka Pharmaceutical Development & Commercialization, Inc. Otsuka and Lundbeck submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD otsuka-us.com

Evidence & citations 22 cited values

Every value below carries the sentence it was read from. 343 sources stand behind the page.

FieldValueCited text
Known as Sertraline “we have restricted the IMPACT list of antidepressants to SSRIs (sertraline, escitalopram, paroxetine, fluoxetine, citalopram), duloxetine, bupropion, and mirtazapine. These...” NCT02458690
331

“In this study, the investigators use selective serotonin reuptake inhibitors (SSRIs, i.e., sertraline, fluoxetine and fluvoxamine)and tricyclic drugs(i.e., clomipramine)...” NCT06942494

“Participants receive only clinical routine antidepressant treatment,Which include fluoxetine (Prozac); sertraline (Zoloft); paroxetine (Paxil); citalopram (Celexa)...” NCT01831440

“Antidepressant medications may include the following: citalopram (Celexa), escitalopram (Lexapro), paroxetine (Paxil CR), sertraline (Zoloft), venlafaxine XR (Effexor XR),...” NCT00564278

“Medication group is a control group that can choose to use the serotonin reuptake inhibitors (SSRIs) approved by China food and Drug Administration (SFDA) for the treatment of...” NCT03558256

“In cases of intolerance or adverse reaction to fluoxetine, the investigator will switch to sertraline (25 to 200mg) or escitalopram (5 to 20mg), the other two antidepressants...” NCT05002309

“Participants assigned to receive the combination therapy may receive one or more of the following medications based on their individual needs: fluoxetine; sertraline;...” NCT00270959

“Participants assigned to receive the combination therapy may receive one or more of the following medications based on their individual needs: fluoxetine, sertraline,...” NCT01347541

“ADT such as citalopram, escitalopram, fluoxetine, sertraline, paroxetine, vilazodone, venlafaxine, desvenlafaxine, duloxetine or bupropion prescribed in accordance with its...” NCT01838876

“Citalopram, ecitalopram, fluoxetine, sertraline, paroxetine IR, paroxetine CR, venlafaxine IR, venlafaxine XR (extended release), desvenlafaxine, duloxetine, mirtazapine,...” NCT02400346

“SSRI (paxil CR, es-citalopram, fluoxetine, sertraline) start with (paxil CR 12.5mg, es-citalopram 10mg, fluoxetine 20mg, sertraline 50mg) for 1 week up to maximal dosage,...” NCT01357967

“Drug: Antidepressant (citalopram, duloxetine, escitalopram, sertraline, or venlafaxine XR) + cariprazine (0.1-0.3 mg/d) Oral, once daily for 8 weeks following an 8 week...” NCT00854100

“Selective Serotonin Reuptake Inhibitor (Escitalopram, 5-10 mg in pregnancy and Sertraline, 12.5-25 mg in postpartum) and/or Benzodiazepine (Alprazolam, 0.25-0.5 mg) will be...” NCT06001021

“SPD489 20mg, 30mg, 50mg, or 70mg + Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine...” NCT01436175

“The dose is 20-60mg/day for fluoxetine, 20-40mg/day for paroxetine, 100-300mg/day for fluvoxamine, 50-200mg/day for sertraline, 20-40mg/day for citalopram, 10-20mg/day for...” NCT05148169

“Participants will receive SSRI antidepressant (such as, citalopram, escitalopram, fluvoxamine, fluoxetine, paroxetine, sertraline, vilazodone or vortioxetine) as a part of...” NCT03321526

“If never taken SSRI or SNRI, commence primary medication arm (SSRI: sertraline, escitalopram or Pregabalin/SNRI: duloxetine, venlafaxine) will be described to patient and will...” NCT04478526

“Administer Toludesvenlafaxine (40-80 mg daily) or imported Sertraline (50-200 mg daily), supplemented with Lorazepam (0.4-0.8 mg) or Alprazolam (0.4-0.8 mg) as needed for sleep support.” NCT07552246

“Antidepressant medications may include any of the following: citalopram, escitalopram, paroxetine, sertraline, venlafaxine XR, bupropion SR, duloxetine, nortriptyline, and mirtazapine.” NCT00742573

“approved by the State Food and Drug Administration (CFDA) for the treatment of OCD (i.e., fluoxetine, paroxetine, sertraline and fluvoxamine) as well as citalopram and escitalopram” NCT05528224

“SSRIs antidepressants, including fluoxetine, paroxetine, sertraline, citalopram, etc., will be administered at oral doses determined by the psychiatrist. Once daily for 6 weeks.” NCT05832619

“quantifying the range of concentration to citalopram, escitalopram, sertraline, fluoxetine, paroxetine, fluvoxamine, duloxetine and venlafaxine in mother plasma and breast milk” NCT01796132

“This study uses SSRIs class drugs, including fluoxetine, paroxetine, fluvoxamine, sertraline, citalopram, and escitalopram, with no specific restrictions on the type of drugs.” NCT06358014

“We made other SSRIs (escitalopram, sertraline) and SNRIs (desvenlafaxine, duloxetine, venlafaxine) our third-line antidepressants, given their negligible effects on weight.” NCT04437485

“ADT such as bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, sertraline, venlafaxine, paroxetine or vilazodone as prescribed by the physician.” NCT01715805

“Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily” NCT01436162

“alternative treatments may include another first-line antidepressant:fluoxetine 20 mg; paroxetine up to 60 mg; sertraline up to 200 mg; bupropion up to 300 mg” NCT02178696

“SSRIs antidepressants, including fluoxetine, paroxetine, sertraline, citalopram, etc., will be administered at oral doses determined by the psychiatrist.” NCT05720637

“SSRIs antidepressants, including fluoxetine, paroxetine, sertraline, citalopram, etc., will be administered at oral doses determined by the psychiatrist.” NCT05605002

“These include fluoxetine, paroxetine, sertraline, fluvoxamine, and others, with tricyclic drugs like clomipramine and SNRIs such as venlafaxine.” NCT06659094

“This study will also evaluate the effectiveness of the SSRI sertraline plus cognitive behavioral therapy (CBT) to treat people with OCD.” NCT00382291

“primary focus will be on serotonin-reuptake inhibiting antidepressant (escitalopram 5-20mg, sertraline 50-200 mg daily) monotherapy” NCT02752542

Sertraline, a selective serotonin reuptake inhibitor (SSRI), is one of the most commonly used antidepressant during pregnancy.” PMID 33751155 Mar 2021

“Test Product: 50 mg sertraline administered as 2.5 mL of Zoloft Oral Solution (20 mg/mL) after dilution with 120 mL of water” NCT03711708

“medication treatment will be a selective serotonin reuptake inhibitor (either fluoxetine, sertraline or escitalopram).” NCT04598230

“selective serotonin reuptake inhibitors (fluoxetine, sertraline, citalopram, escitalopram, paroxetine or fluvoxamine)” NCT03993535

“Patients will receive 16 weeks of treatment with either a SSRI (sertraline or paroxetine) or a SNRI (venlafaxine).” NCT00745017

“serotonin reuptake inhibitors (fluoxetine 20 - 80 mg/day, paroxetine 20 - 60 mg/day, sertraline 50 - 200 mg/day)” NCT02300051

“Patients will begin 12 weeks of sertraline treatment initiated at a daily dose of 50 mg for the first 4 weeks.” NCT07015944

“Participants will receive selective serotonin reuptake inhibitors (SSRIs) such as Sertraline over six weeks.” NCT06955845

“Duloxetine, escitalopram, fluoxetine, paroxetine IR, sertraline, venlafaxine XR; dosing according to label” NCT01838681

“a choice of 3 selective serotonin reuptake inhibitors (SSRIs; ie, sertraline, fluoxetine, or paroxetine)” PMID 41091477 Dec 2025

“The second group has administered sertralin (50mg)+ketoprofen (100mg) (Sertraline \& Ketoprofen) daily.” NCT03514810

sertraline: 100-200mg, citalopram 20-40mg, escitalopram 10-20mg, paroxetine 20-60mg; fluoxetine 20-80mg” NCT01903447

“Adjunctive antidepressant agents: nortriptyline, duloxetine, sertraline, trazodone, or mirtazapine” NCT01943435

“50 mg/day of sertraline plus omega-3 FA or 50 mg/day of sertraline plus placebo for 10 weeks.” NCT02021669

“SSRI treated group are depressive patients treated with fluoxetine, paroxetine or sertralineNCT01237275

“SSRI treated group is depressive patients treated with fluoxetine, paroxetine, or sertralineNCT00817375

“AD: aripiprazole, bupropion, duloxetine, escitalopram, mirtazapine, sertraline, venlafaxine” NCT04747314

“Patients will receive the "treatment as usual" with a SSRI: sertraline or citalopram.” NCT02262156

“which included escitalopram, sertraline, and desvenlafaxine in a prescribed sequence.” PMID 27788313 Oct 2016

“Drug: Sertraline positive control Drug: Placebo placebo to Ammoxetine hydrochlorid.” NCT06827431

Sertraline 50 mg/day or Duloxetine 60 mg/day or Bupropion XL 150-300 mg/day” NCT07654179

“fluoxetine, paroxetine, sertraline, fluvoxamine, escitalopram, clomipramine” NCT02431845

“Escitalopram, 20mg-40mg daily or Sertraline 50-150 mg daily for 12 weeks” NCT02137369

“Fluoxetine, escitalopram, citalopram, fluvoxamine, or sertralineNCT03222570

“The treatment will start with Sertraline (SSRI) - doses of 50 mg” NCT06467474

“the other receiving an SSRI (e.g., sertraline or escitalopram)” NCT06957223

“paroxetine, fluoxetine, sertraline, escitalopram, citalopram” NCT00944996

Sertraline (according to response, and tolerance)25-200mg” NCT01000402

“Oral sertraline administered once daily in the morning” NCT07478796

sertraline (50 mg, increased to 100 to 150 mg)” NCT00118430

“ASC-01 (aripiprazole/sertraline combination)” NCT02046564

“fluoxetine (Prozac); sertraline (Zoloft)” NCT01460212

“escitalopram, citalopram or sertralineNCT02279953

sertraline hydrochloride 50-200mg/day” NCT02023567

“- Sertraline 50-200 mg/d. N06AB06” NCT01305707

“Arm 1: Sertraline (Zoloft) 50 mg” NCT00066859

sertraline (Zoloft and others)” NCT01944657

sertraline (Zoloft®) tablets” NCT03538691

Sertraline (Zoloft) 25-200;” NCT00074815

Sertraline, "Zoloft"” NCT02358343

Sertraline (Zoloft)” NCT00797966

Sertraline, Zoloft” NCT01916824

sertraline_Zoloft” NCT01352572

sertraline_Zoloft” NCT01352559

sertraline_Zoloft” NCT00817011

sertraline_Zoloft” NCT01228357

SertralineNCT00864019

sertralineNCT01488266

sertralineNCT00157547

NCT00655174

NCT00179257

NCT00677352

NCT07645157

NCT00262223

NCT00150306

NCT06081348

NCT03978286

NCT00644982

NCT03414931

NCT04977544

NCT00001483

NCT06965569

NCT00864019

NCT07574060

NCT02777372

NCT00581009

NCT02493868

NCT01802385

NCT00215241

NCT02917122

NCT00004554

NCT00057642

NCT01467804

NCT00955474

NCT05683223

NCT02463110

NCT00636246

NCT03434041

NCT00917397

NCT02565316

NCT02179268

NCT01977729

NCT03068429

NCT00178828

NCT00536198

NCT05273996

NCT01669304

NCT01794455

NCT00531518

NCT00491478

NCT00232167

NCT03779789

NCT00143091

NCT00744328

NCT01360866

NCT00331305

NCT02520726

NCT01764867

NCT02022709

NCT02385799

NCT00229476

NCT00232284

NCT01305889

NCT03002012

NCT04430556

NCT01109693

NCT00182533

NCT00198094

NCT04963257

NCT01993017

NCT00787501

NCT00391430

NCT01896349

NCT02918097

NCT01114100

NCT02901249

NCT00234312

NCT00262470

NCT06025474

NCT01703039

NCT01214382

NCT01309074

NCT00680602

NCT00325000

NCT00056472

NCT00701675

NCT03033069

NCT00340379

NCT02285699

NCT05646693

NCT00233103

NCT00283192

NCT02655354

NCT06357104

NCT00158990

NCT04637620

NCT04476030

NCT00835627

NCT02268487

NCT00133822

NCT01254305

NCT00169988

NCT00177996

NCT01769027

NCT02908334

NCT00508859

NCT00302068

NCT04171193

NCT03469128

NCT00284791

NCT00299611

NCT04539951

NCT03852160

NCT02237937

NCT01287494

NCT00000378

NCT00519012

NCT00000384

NCT00118417

NCT00078286

NCT02374567

NCT07539805

NCT02469545

NCT00001777

NCT07318181

NCT00969852

NCT00318773

NCT04388202

NCT02955719

NCT00836667

NCT00182078

NCT00215150

NCT00080158

NCT00693849

NCT00834652

NCT06704594

NCT00026637

NCT01454635

NCT01155531

NCT00127673

NCT00005013

NCT01250873

NCT01113164

NCT00282828

NCT05973786

NCT01028482

NCT00648856

NCT01437189

NCT07025590

NCT06725771

NCT02739061

NCT01524133

NCT01427608

NCT01751828

NCT02417064

NCT00009191

NCT06698666

NCT00421369

NCT06840379

NCT00118014

NCT02770378

NCT02228005

NCT00048854

NCT00873795

NCT02418585

NCT00177424

NCT00602355

NCT04183205

NCT06408246

NCT00339066

NCT02347033

NCT00375843

NCT02452983

NCT01033084

NCT00744406

NCT05950061

NCT00000440

NCT05537584

NCT00704379

NCT02813447

NCT02641652

NCT00086138

NCT00276900

NCT05603104

NCT00485862

NCT00050804

NCT02422186

NCT02504931

NCT00368550

NCT00159965

NCT04094870

NCT01032018

NCT04076371

NCT07139834

NCT02122393

NCT00245557

NCT02189213

NCT01235195

NCT01027559

NCT00058903

NCT00594269

NCT01407094

NCT03279471

NCT00000446

NCT00836849

NCT02797808

NCT05814640

NCT05892744

NCT00406952

NCT03841474

NCT00275197

NCT01032434

NCT00015132

NCT00946998

NCT00650325

NCT04124614

NCT00654953

NCT07192367

NCT02269540

NCT00351910

NCT00249431

NCT00052078

NCT02497287

NCT04221997

NCT05341843

NCT00000451

NCT00263133

NCT00043550

NCT00208702

NCT00208585

NCT07011693

NCT00021528

NCT00612807

NCT06384209

NCT02175602

NCT00276965

NCT06796946

NCT00864344

NCT00857584

NCT01178671

NCT00666757

NCT00000458

NCT00374426

NCT00624013

NCT01896934

NCT03179839

NCT04174170

NCT01856127

NCT06124417

NCT02891278

NCT02651623

NCT02235064

NCT00078767

NCT05588102

NCT00179283

NCT00116857

NCT01098318

NCT01569685

NCT00208117

NCT01474746

Known as Aremis ChEMBL registry synonym — accepted as the source's own label CHEMBL809
Known as Besitron ChEMBL registry synonym — accepted as the source's own label CHEMBL809
Known as CP-51,974-1 ChEMBL registry synonym — accepted as the source's own label CHEMBL809
Known as Lustral “Sertraline hydrochloride (trade names Zoloft, Lustral) is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class.” NCT01856127
Known as NSC-746308 ChEMBL registry synonym — accepted as the source's own label CHEMBL809
Known as NSC-758948 ChEMBL registry synonym — accepted as the source's own label CHEMBL809
Known as SER “The purpose of this study is to compare 3 treatments for children with OCD: medication (sertraline, SER) alone vs OCD-specific therapy (Cognitive Behavior Therapy, CBT) vs...” NCT00000384
Known as Sertralin ClinicalTrials.gov intervention name — accepted as the source's own label NCT00433121
2

NCT00226642

NCT03514810

Known as Sertralina ChEMBL registry synonym — accepted as the source's own label CHEMBL809
Known as Sertraline (as hydrochloride) ChEMBL registry synonym — accepted as the source's own label CHEMBL809
Known as Sertraline HCl Sertraline HCl 100 mg tablets, single dose” NCT00864344
1

NCT02473783

Known as sertraline hydrochloride “This study is designed to determine differences in drug exposure in subjects after being administered 50 mg tablets of sertraline hydrochloride as compared to drug exposure...” NCT01235195
7

“The objective of this study was to investigate the bioequivalence of Mylan's sertraline hydrochloride 100 mg tablets to Pfizer's Zoloft® 100 mg tablets following a single, oral...” NCT00648856

Sertraline hydrochloride is a selective serotonin reuptake inhibitor which established improvement in itching in patients with cholestatic pruritis.” NCT05341843

Sertraline hydrochloride (trade names Zoloft, Lustral) is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class.” NCT01856127

Sertraline hydrochloride 100 mg tablets (test) versus Zoloft® (reference)” NCT00836849

Sertraline hydrochloride 100 mg tablets (test) versus Zoloft® (reference)” NCT00836667

Sertraline Hydrochloride Tablets 100 mg” NCT00650325

NCT00004300

Known as Sertraline, Zoloft “Sertraline, "Zoloft"” NCT02358343
3

“sertraline (Zoloft)” NCT01460212

Sertraline, ZoloftNCT01916824

sertraline, zoloftNCT01114100

Known as SRT “sertraline (SRT), cognitive behavioral therapy” PMID 22122292 Dec 2011
1

“sertraline (SRT, n = 133)” PMID 25721183 Dec 2014

Known as Zoloft “Participants receive only clinical routine antidepressant treatment,Which include fluoxetine (Prozac); sertraline (Zoloft); paroxetine (Paxil); citalopram (Celexa)...” NCT01831440
37

“Antidepressant medications may include the following: citalopram (Celexa), escitalopram (Lexapro), paroxetine (Paxil CR), sertraline (Zoloft), venlafaxine XR (Effexor XR),...” NCT00564278

“The objective of this study was to investigate the bioequivalence of Mylan's sertraline hydrochloride 100 mg tablets to Pfizer's Zoloft® 100 mg tablets following a single, oral...” NCT00648856

“The purpose of this study is to document the efficacy of sertraline (Zoloft) in the treatment of depression (major depressive disorder) after TBI, including the impact on...” NCT00233103

“The purpose of this study is to understand changes in brain chemical signals when people take antidepressants called sertraline (Zoloft®) and bupropion (Wellbutrin SR, Zyban ®).” NCT00178828

“The purpose of the study is to evaluate the efficacy and safety of flexible doses of escitalopram (Lexapro) compared to sertraline (Zoloft) for treatment of Dysthymic Disorder.” NCT00234312

“in fluoxetine (Prozac)-resistant adolescents with Major Depressive Disorder (MDD), Lamotrigine plus fluoxetine will be safe and as effective as sertraline (Zoloft).” NCT00284791

“the efficacy of the serotonergic medication sertraline (Zoloft) in the treatment and prevention of posttraumatic psychiatric sequelae in ASD victims.” NCT00050804

“Admnistration of 18FAV45 if patient is compliant with one of those treatment: Seroplex, Zoloft, Deroxat, Venlafaxine, Mirtazapine, Moclamine,” NCT01962753

“Patients are assigned randomly (like tossing a coin) to receive St. John's wort, Sertraline (Zoloft), or a placebo (sugar pill) for 8 weeks.” NCT00005013

“This study is a control trial of sertraline (Zoloft) in children aged 2 to 5 years old inclusive with Autism Spectrum Disorder.” NCT02385799

“administer/prescribe the common antidepressant medication, sertraline (tradename Zoloft), track symptom response over time” NCT05892744

“examine the effectiveness of the FDA-approved medication sertraline (Zoloft) for major depression.” NCT00177996

“To study the effectiveness of sertraline (Zoloft) in treating depression in adults with diabetes.” NCT00374426

“All qualified participants will be started on sertraline (Zoloft) for eight weeks.” NCT00133822

“Sertraline (Zoloft) works as a selective serotonin reuptake inhibitor (SSRI).” NCT00001483

“adding sertraline (Zoloft®) to Trauma-Focused Cognitive Behavioral Therapy” NCT00078767

“Sertraline (Zoloft), daily, for 16 weeks.” NCT00302068

Zoloft® 100 mg tablets, single dose” NCT00864344

“sertraline (Zoloft and others)” NCT01944657

“sertraline (Zoloft®) tablets” NCT03538691

“Sertraline (Zoloft) 25-200;” NCT00074815

“Sertraline [Zoloft]” NCT00009191

“Sertraline (Zoloft)” NCT00208117

“sertraline (Zoloft)” NCT00000458

“Sertraline (Zoloft)” NCT00797966

“sertraline (Zoloft)” NCT00000446

“Sertraline (Zoloft)” NCT00331305

“sertraline (Zoloft)” NCT00000440

“sertraline (Zoloft)” NCT00229476

“sertraline (Zoloft)” NCT00179257

“Sertraline (Zoloft)” NCT00086138

“sertraline (Zoloft)” NCT00004554

“sertraline_ZoloftNCT00817011

NCT04071639

NCT02042573

NCT01477268

NCT06778824

Known as Zoloft (Registered) “A Phase 1, Single Center Randomized, Three-way Crossover, Double-blinded, Placebo- And Moxifloxacin-controlled Thorough Qt (Tqt) Study To Determine The Effects Of Sertraline...” NCT02651623
Known as Zoloft Oral Solution “Test Product: 50 mg sertraline administered as 2.5 mL of Zoloft Oral Solution (20 mg/mL) after dilution with 120 mL of water” NCT03711708
Action Inhibit “acts centrally to selectively block serotonin uptake” NCT00001777
1

“Serotonin transporter inhibitor” CHEMBL809

Modality Small molecule “Selective Serotonin Reuptake Inhibitor” NCT00043550
Route Oral “FLD patients will undergo a controlled clinical trial of an orally administered serotonergic agent (Sertraline)” NCT00001777
Target SLC6A4 “Serotonin transporter inhibitor” CHEMBL809